newsfilter
← Earnings
Earnings Releases·

Moleculin Biotech — Third Quarter 2026 Earnings Summary

Moleculin Biotech completed treatment for all 90 patients in Part A of its pivotal MIRACLE trial evaluating Annamycin for relapsed or refractory acute myeloid leukemia, with comprehensive data expected in the first quarter of 2027. A peer-reviewed analysis of 90 patients across five clinical trials found no evidence of clinical or subclinical cardiotoxicity, supporting the drug's differentiated safety profile. The company reported a net loss of approximately $6.5 million for the third quarter of 2026, driven primarily by research and development expenses related to the MIRACLE trial. Additionally, new preclinical data suggest Annamycin may convert immunologically cold pancreatic tumors to hot, supporting potential combination therapies.

Company
MOLECULIN BIOTECH INC
Sector
Healthcare
Industry
Biotechnology